158 related articles for article (PubMed ID: 27056913)
1. Proteomic Insight Reveals Elevated Levels of Albumin in Circulating Immune Complexes in Diabetic Plasma.
Bhat S; Jagadeeshaprasad MG; Patil YR; Shaikh ML; Regin BS; Mohan V; Giri AP; Balasubramanyam M; Boppana R; Kulkarni MJ
Mol Cell Proteomics; 2016 Jun; 15(6):2011-20. PubMed ID: 27056913
[TBL] [Abstract][Full Text] [Related]
2. Aminoguanidine reduces regional albumin clearance but not urinary albumin excretion in streptozotocin-diabetic rats.
Huijberts MS; Wolffenbuttel BH; Crijns FR; Nieuwenhuijzen Kruseman AC; Bemelmans MH; Struijker Boudier HA
Diabetologia; 1994 Jan; 37(1):10-4. PubMed ID: 8150221
[TBL] [Abstract][Full Text] [Related]
3. Blockade of advanced glycation end-product formation restores ischemia-induced angiogenesis in diabetic mice.
Tamarat R; Silvestre JS; Huijberts M; Benessiano J; Ebrahimian TG; Duriez M; Wautier MP; Wautier JL; Lévy BI
Proc Natl Acad Sci U S A; 2003 Jul; 100(14):8555-60. PubMed ID: 12805564
[TBL] [Abstract][Full Text] [Related]
4. Growth arrest specific 2-like protein 1 expression is upregulated in podocytes through advanced glycation end-products.
Liebisch M; Bondeva T; Franke S; Hause S; Wolf G
Nephrol Dial Transplant; 2017 Apr; 32(4):641-653. PubMed ID: 27638909
[TBL] [Abstract][Full Text] [Related]
5. Role of maltol in advanced glycation end products and free radicals: in-vitro and in-vivo studies.
Kang KS; Yamabe N; Kim HY; Yokozawa T
J Pharm Pharmacol; 2008 Apr; 60(4):445-52. PubMed ID: 18380916
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of advanced glycation endproduct (AGE) rescues against streptozotocin-induced diabetic cardiomyopathy: Role of autophagy and ER stress.
Pei Z; Deng Q; Babcock SA; He EY; Ren J; Zhang Y
Toxicol Lett; 2018 Mar; 284():10-20. PubMed ID: 29174818
[TBL] [Abstract][Full Text] [Related]
7. Effect of age receptor blocker and/or anti-inflammatory coadministration in relation to glycation, oxidative stress and cytokine production in stz diabetic rats.
El-seweidy MM; El-Swefy SE; Ameen RS; Hashem RM
Pharmacol Res; 2002 May; 45(5):391-8. PubMed ID: 12123627
[TBL] [Abstract][Full Text] [Related]
8. Circulating advanced glycation peptides in streptozotocin-induced diabetic rats: evidence for preferential modification of IgG light chains.
Gugliucci A; Menini T
Life Sci; 1998; 62(23):2141-50. PubMed ID: 9627093
[TBL] [Abstract][Full Text] [Related]
9. Effects of aminoguanidine on peripheral nerve function and polyol pathway metabolites in streptozotocin-diabetic rats.
Cameron NE; Cotter MA; Dines K; Love A
Diabetologia; 1992 Oct; 35(10):946-50. PubMed ID: 1451951
[TBL] [Abstract][Full Text] [Related]
10. A quick, simple method for detecting circulating fluorescent advanced glycation end-products: Correlation with in vitro and in vivo non-enzymatic glycation.
Villa M; Parravano M; Micheli A; Gaddini L; Matteucci A; Mallozzi C; Facchiano F; Malchiodi-Albedi F; Pricci F
Metabolism; 2017 Jun; 71():64-69. PubMed ID: 28521879
[TBL] [Abstract][Full Text] [Related]
11. Effect of protocatechualdehyde on receptor for advanced glycation end products and TGF-beta1 expression in human lens epithelial cells cultured under diabetic conditions and on lens opacity in streptozotocin-diabetic rats.
Kim YS; Kim NH; Lee SW; Lee YM; Jang DS; Kim JS
Eur J Pharmacol; 2007 Aug; 569(3):171-9. PubMed ID: 17597607
[TBL] [Abstract][Full Text] [Related]
12. The breakdown of preformed advanced glycation end products reverses erectile dysfunction in streptozotocin-induced diabetic rats: preventive versus curative treatment.
Usta MF; Kendirci M; Gur S; Foxwell NA; Bivalacqua TJ; Cellek S; Hellstrom WJ
J Sex Med; 2006 Mar; 3(2):242-50; discussion 250-2. PubMed ID: 16490017
[TBL] [Abstract][Full Text] [Related]
13. Proteomic analysis of protease resistant proteins in the diabetic rat kidney.
Bansode SB; Chougale AD; Joshi RS; Giri AP; Bodhankar SL; Harsulkar AM; Kulkarni MJ
Mol Cell Proteomics; 2013 Jan; 12(1):228-36. PubMed ID: 23118466
[TBL] [Abstract][Full Text] [Related]
14. Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis.
Forbes JM; Yee LT; Thallas V; Lassila M; Candido R; Jandeleit-Dahm KA; Thomas MC; Burns WC; Deemer EK; Thorpe SR; Cooper ME; Allen TJ
Diabetes; 2004 Jul; 53(7):1813-23. PubMed ID: 15220206
[TBL] [Abstract][Full Text] [Related]
15. Potential benefit of inhibitors of advanced glycation end products in the progression of type II diabetes: a study with aminoguanidine in C57/BLKsJ diabetic mice.
Piercy V; Toseland CD; Turner NC
Metabolism; 1998 Dec; 47(12):1477-80. PubMed ID: 9867077
[TBL] [Abstract][Full Text] [Related]
16. Detection of autoantibodies against advanced glycation endproducts and AGE-immune complexes in serum of patients with diabetes mellitus.
Turk Z; Ljubic S; Turk N; Benko B
Clin Chim Acta; 2001 Jan; 303(1-2):105-15. PubMed ID: 11163030
[TBL] [Abstract][Full Text] [Related]
17. Effects of aminoguanidine in preventing experimental diabetic nephropathy are related to the duration of treatment.
Soulis T; Cooper ME; Vranes D; Bucala R; Jerums G
Kidney Int; 1996 Aug; 50(2):627-34. PubMed ID: 8840295
[TBL] [Abstract][Full Text] [Related]
18. Plasma Proteins Modified by Advanced Glycation End Products (AGEs) Reveal Site-specific Susceptibilities to Glycemic Control in Patients with Type 2 Diabetes.
Greifenhagen U; Frolov A; Blüher M; Hoffmann R
J Biol Chem; 2016 Apr; 291(18):9610-6. PubMed ID: 26933035
[TBL] [Abstract][Full Text] [Related]
19. Effect of aminoguanidine on lipid peroxidation in streptozotocin-induced diabetic rats.
Ihm SH; Yoo HJ; Park SW; Ihm J
Metabolism; 1999 Sep; 48(9):1141-5. PubMed ID: 10484054
[TBL] [Abstract][Full Text] [Related]
20. Identification of megakaryocytes as a target of advanced glycation end products in diabetic complications in bone marrow.
Wang B; Yu J; Wang T; Shen Y; Lin D; Xu X; Wang Y
Acta Diabetol; 2018 May; 55(5):419-427. PubMed ID: 29417230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
